newsfilter
← Earnings
Earnings Releases·

Sagimet Biosciences — Third Quarter 2026 Earnings Summary

Sagimet Biosciences initiated its registrational U.S. AURORA Phase 3 clinical trial for denifanstat in moderate to severe acne, with topline data expected in the second half of 2027. The company completed an underwritten offering of Series A common stock and pre-funded warrants in October 2026, generating $115 million in gross proceeds. As of September 30, 2026, Sagimet reported a pro forma cash balance of approximately $356 million, which is projected to fund operations through mid-2029. Additionally, the company presented positive 52-week efficacy data from its license partner Ascletis' Phase 3 trial in China and announced plans to initiate a Phase 2 trial for its FASN inhibitor TVB-3567 before the end of 2026.

Company
SAGIMET BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology